Medtech

Even amid a government shutdown – and in some ways because of it – 4Q25 promises a large number of policy catalysts across the medtech, diagnostics, life science tools (LST), and biopharma landscapes, informing company…

We remain cautiously optimistic that any eventual longer-term FY26 funding bill will include legislation allowing – but not requiring – Medicare coverage of multi-cancer early detection (MCED) screening [GH, EXAS, GRAL]. Larger firms may nevertheless…

Despite the nearly ubiquitous opposition of stakeholders, we think CMS will likely finalize its intention to include continuous glucose monitors (CGMs) [DXCM, ABT] in the next round of the Competitive Bidding Program (CBP), along with…

With CMS reopening its coverage policy for colorectal cancer (CRC) screening yesterday after the close, it seems likely that the space will get a bit more crowded for EXAS and GH, as we would expect…

We remain skeptical of Merit Medical’s (MMSI) prospects for a Medicare hospital outpatient transitional pass-through (TPT) payment for its Wrapsody Cell Impermeable Endoprosthesis (CIE), following confirmation of its application last week, setting it up for…

We view the FY26 NIH funding bill released by the House Appropriations Committee last night, in advance of its markup at 5pm ET this afternoon, as positive for life science tools (LST) manufacturers, with both…

With the House Appropriations health subcommittee announcing a markup of its FY26 HHS funding bill on Tues., Sept. 2 [available here], we maintain our view that topline funding numbers for NIH will likely remain flat…

This morning’s Senate Appropriations Committee’s markup of the FY26 Labor / HHS funding bill, which includes a $400M increase (+0.8% YoY) for NIH, should serve as an interim clearing event for life science tools (LST)…

We view CMS’s clinical laboratory advisory panel today as an incremental positive for Guardant Health (GH), despite what appears to be a lack of endorsement for the company’s request that payments for Reveal (0569U: $1,644)…

With shares of MMSI off today – we suspect in part on investor disappointment over the lack of any discussion of the company’s Transitional Pass-Through (TPT) payment application for its Wrapsody product in CMS’s CY26…